Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
ProShares Ultra Nasdaq Biotechnology(BIB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIB
10/23/2026: BIB (2-star) is currently NOT-A-BUY. Pass it for now.
BIB is a leveraged ETF designed to provide 2x the daily return of the Nasdaq Biotechnology Index using derivative instruments. Its primary strength lies in its ability to offer magnified exposure for tactical traders, though this comes with high risks, including compounding decay over time and significant sector-specific concentration. It is best suited for experienced investors looking to capitalize on short-term market momentum rather than those seeking long-term growth. Investors must closely monitor sector news, market volatility, and the negative impact of holding these instruments for extended periods. Key risks include the inherent structural decay of leveraged products and the binary nature of biotech stock performance.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This fund is designed for short-term tactical capture rather than long-term growth investing. |
| Momentum investor | Strong fit while signal remains positive | The 2x leverage enhances momentum plays during strong, short-term upward trends in the biotech sector. |
| Value investor | Weak fit | The daily rebalancing mechanism and leverage decay are fundamentally misaligned with value-based investment strategies. |
| Dividend/Income investor | Weak fit | Leveraged ETFs are not intended for income generation and typically do not provide consistent dividends. |
| Low-risk investor | Weak fit | The high leverage and sector concentration make this unsuitable for risk-averse investors. |
Investor Profile
Ideal Investor Profile
Sophisticated, active traders with a high risk tolerance who understand leveraged ETF mechanics.
Suitability
This fund is strictly for short-term tactical trading and is not suitable for passive, long-term buy-and-hold investors.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The 2x daily leverage objective inherently magnifies market volatility. |
| Market risk | High | Exposure to the biotech sector is subject to intense regulatory, clinical, and pricing risks. |
| Concentration | High | The fund is focused solely on the biotechnology industry, leaving it vulnerable to sector-specific downturns. |
| Tracking/expense | Medium / high | Daily rebalancing and compounding effects cause the fund to deviate significantly from the index over time. |
| Liquidity | Medium | While generally liquid, market conditions can impact the ability to exit positions at desired prices. |
| Business/sector quality | Medium / high | Biotech firms often rely on speculative R&D success, introducing significant business quality risk. |
Risk Analysis
Volatility
BIB exhibits extremely high historical volatility due to the 2x leverage multiplier applied to an already volatile biotech sector.
Market Risk
The primary risk is the concentrated exposure to biotechnology, where stock prices are often binary based on clinical trial success or regulatory decisions.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Nasdaq Biotechnology Index — seeks 2x daily return | 98 | This represents the primary underlying index exposure which the fund aims to amplify daily. |
| Cash/collateral | Cash and Cash Equivalents | 2 | Cash is held to manage daily liquidity and collateral requirements for swap agreements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 73.91% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.